Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colistin Nephrotoxicity and Role of Alpha Lipoic Acid
Sponsor: Helwan University
Summary
Nephrotoxicity is a great concern in patients receiving intravenous colistin and there is a disparity in the reported rates between previous studies. Several preclinical researches studied the effect of the antioxidants (e.g. L.carnitine, vitamin C, vitamin E, N-acetyl cysteine, and alpha lipoic acid) in reducing the risk of colistin-induced nephrotoxicity but there is a lack of clinical studies on human. Due to the paucity of studies that early predict colistin-induced nephrotoxicity using early acute kidney injury "AKI" biomarkers e.g. kidney injury molecule 1"KIM1" and the lack of human studies that evaluate the role of alpha lipoic acid in ameliorating colistin-induced nephrotoxicity, so this study will be conducted.
Official title: Colistin Nephrotoxicity in Hospitalized Patients: The Role of Biomarkers in Guiding the Preventive Strategies
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2026-06-30
Completion Date
2027-02-28
Last Updated
2026-06-25
Healthy Volunteers
No
Conditions
Interventions
alpha lipoic acid drug (thioctic acid acid)
Oral alpha-lipoic acid will be administered at the start of colistin therapy till the end of the colistin course by a dose of 600 mg every 8 hours to be taken 30 min before meals in the intervention group.
Locations (2)
6th October Hospital-Dokki-General Authority for Health Insurance Organization
Giza, Egypt
Al-Haram Hospital
Giza, Egypt